Industries

• Reset all ×
• Life Sciences ×

Showing 471–480 of 506 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  Ulcerative Colitis (UC) Market in China 2021

  The ulcerative colitis (UC) market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 16.5% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the ulcerative colitis (UC) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Pulmonary Arterial Hypertension (PAH) Market in China 2021

  The pulmonary arterial hypertension (PAH) market in China in terms of revenue is set to grow by US$ 787 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 49.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pulmonary arterial hypertension (PAH) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Pemetrexed Pharmaceutical Market in China 2021

  The pemetrexed pharmaceutical market in China in terms of revenue is set to grow by US$ 443 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.1% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pemetrexed pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Central Nervous System Pharmaceutical Market in China 2021

  The central nervous system pharmaceutical market in China in terms of revenue is set to grow by US$ 10 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the central nervous system pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Edaravone Pharmaceutical Market in China 2021

  The edaravone pharmaceutical market in China in terms of revenue is expected to decline at a compound annual growth rate (CAGR) of -0.8% from US$ 426 million in 2020 to 429 million in 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the edaravone pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Autoimmune Pharmaceutical Market in China 2021

  The autoimmune pharmaceutical market in China in terms of revenue is set to grow by US$ 12 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 26.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the autoimmune pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) Market in China 2021

  The conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market in China in terms of revenue is set to grow by US$ 442 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the conventional synthetic disease-modifying antirheumatic drugs (DMARDs) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Rheumatoid Arthritis Pharmaceutical Market in China 2021

  The rheumatoid arthritis pharmaceutical market in China in terms of revenue is set to grow by US$ 7 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 21.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the rheumatoid arthritis pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Biological Pharmaceuticals for Autoimmune Diseases Market in China 2021

  The biological pharmaceuticals for autoimmune diseases market in China in terms of revenue is set to grow by US$ 9 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 42.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biological pharmaceuticals for autoimmune diseases market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Non-Steroidal Anti-Inflammatory Pharmaceuticals Market in China 2021

  The non-steroidal anti-inflammatory pharmaceuticals market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-steroidal anti-inflammatory pharmaceuticals market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450